Last reviewed · How we verify
Triamcinolone Injection
Triamcinolone is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.
Triamcinolone is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors. Used for Rheumatoid arthritis, Systemic lupus erythematosus, Polymyalgia rheumatica.
At a glance
| Generic name | Triamcinolone Injection |
|---|---|
| Also known as | Kenalog Injection, Kenacort 40©, TAC |
| Sponsor | University of Miami |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Dermatology |
| Phase | FDA-approved |
Mechanism of action
Triamcinolone works by entering cells and binding to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene expression. This leads to decreased production of pro-inflammatory cytokines, reduced immune cell activation and migration, and suppression of inflammatory mediators. The result is broad anti-inflammatory and immunosuppressive effects.
Approved indications
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Polymyalgia rheumatica
- Giant cell arteritis
- Inflammatory joint conditions
- Dermatological inflammatory conditions
Common side effects
- Hyperglycemia
- Hypertension
- Osteoporosis
- Infection risk
- Insomnia
- Mood changes
- Injection site reactions
Key clinical trials
- Dose Dependent Steroid Injections (PHASE4)
- A Norwegian Trial Comparing Treatment Strategies for Carpal Tunnel Syndrome (PHASE4)
- Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone (PHASE4)
- USG-Guided Shoulder Injections in Frozen Shoulder (NA)
- Local Methotrexate Injections for the Treatment of Nail Psoriasis (PHASE4)
- Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation (PHASE2)
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- Corticosteroid Meniscectomy Randomized Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |